Trousseau syndrome (cancer-associated thrombosis)
Thrombosis · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Hypercoagulability of malignancy causing recurrent, migratory or unusual-site venous (and arterial) thromboses, sometimes as the presenting feature of occult cancer.
Red flags
- Recurrent thrombosis despite anticoagulation
- Unusual-site thrombosis
- Arterial events
- Marfanoid coagulopathy / DIC features
Assessment
Differential diagnosis
- Provoked / unprovoked venous thromboembolism
- Antiphospholipid syndrome
- Heparin-induced thrombocytopenia
- Paroxysmal nocturnal haemoglobinuria
- Vasculitis
Investigations
- Doppler / CT to confirm thrombosis
- FBC, coagulation, D-dimer
- Review for underlying malignancy
- Renal and liver function
- Age-appropriate cancer screening
Management
- Confirm and treat the acute thrombosis
- Anticoagulate (low-molecular-weight heparin often preferred)
- Assess for occult malignancy
- Manage the underlying cancer
- Monitor for recurrent thrombosis despite anticoagulation
- Haematology / oncology involvement
Drugs & doses
Low-molecular-weight heparin (often preferred in cancer)
Direct oral anticoagulant in selected cancers (specialist)
Manage the underlying malignancy
Disposition
Anticoagulate; investigate for malignancy.
Complications & pitfalls
- Recurrent thromboembolism
- Pulmonary embolism
- Non-bacterial thrombotic endocarditis with emboli
Exam pearls
- Migratory or unusual-site thrombosis should prompt a cancer search.
- LMWH has traditionally been favoured over warfarin in cancer-associated thrombosis.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.